Bio-Rad Laboratories EVP James Barry Receives RSU Grant and Settles Vesting Shares

Executive Summary

On September 9, 2026, Bio-Rad Laboratories, Inc. ($BIO) reported Form 4 activity for James Barry, Executive Vice President and President of the Life Science Group (LSG). The filing details routine executive equity compensation events occurring between September 4 and September 6, 2026, including a new grant of restricted stock units (RSUs), the vesting of existing RSUs, and mandatory tax withholding.

---

Transaction Breakdown

1. Derivative Grant (September 4, 2026):

   • Security: Restricted Stock Units
   • Amount: 4,313 units granted at $0.00.
   • Vesting Schedule: 25% on the first anniversary, with the remainder vesting in equal quarterly installments over four years.

2. Vesting of Existing Awards (September 5 & 6, 2026):

   • September 5, 2026: 1,027 RSUs vested and converted to Class A Common Stock (Code M).
   • September 6, 2026: 1,056 RSUs vested and converted to Class A Common Stock (Code M).
   • Total Acquired via Vesting: 2,083 shares.

3. Tax Withholding / Surrendered Shares (Code F):

   • September 5, 2026: 369 shares withheld at $386.11 per share ($142,474.59).
   • September 6, 2026: 470 shares withheld at $386.11 per share ($181,471.70).
   • Total Shares Surrendered for Taxes: 839 shares (~$323,946.29 total value).

---

Post-Transaction Holdings

• Direct Class A Common Stock: 2,024.682 shares
• Unvested Restricted Stock Units: 9,508 units across various grant tranches.

---

Market & Strategic Significance

• Trading Significance: Low
• These transactions represent standard executive equity compensation grant and vesting cycles, along with automatic share surrender for statutory tax withholding obligations. No open-market purchases or discretionary open-market sales took place.